The Combined Dexamethasone/CRH Test (DEX/CRH Test) and Prediction of Acute Treatment Response in Major Depression by Schüle, Cornelius et al.
The Combined Dexamethasone/CRH Test (DEX/CRH Test)
and Prediction of Acute Treatment Response in Major
Depression
Cornelius Schu ¨le*, Thomas C. Baghai, Daniela Eser, Sibylle Ha ¨fner, Christoph Born, Sascha Herrmann,
Rainer Rupprecht
Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich, Munich, Germany
Abstract
Background: In this study the predictive value of the combined dexamethasone/CRH test (DEX/CRH test) for acute
antidepressant response was investigated.
Methodology/Principal Findings: In 114 depressed inpatients suffering from unipolar or bipolar depression (sample 1) the
DEX/CRH test was performed at admission and shortly before discharge. During their stay in the hospital patients received
different antidepressant treatment regimens. At admission, the rate of nonsuppression (basal cortisol levels .75.3 nmol/l)
was 24.6% and was not related to the later therapeutic response. Moreover, 45 out of 114 (39.5%) patients showed an
enhancement of HPA axis function at discharge in spite of clinical improvement. In a second sample, 40 depressed patients
were treated either with reboxetine or mirtazapine for 5 weeks. The DEX/CRH test was performed before, after 1 week, and
after 5 weeks of pharmacotherapy. Attenuation of HPA axis activity after 1 week was associated with a more pronounced
alleviation of depressive symptoms after 5-week mirtazapine treatment, whereas downregulation of HPA system activity
after 5 weeks was related to clinical response to reboxetine. However, early improvement of HPA axis dysregulation was not
necessarily followed by a beneficial treatment outcome.
Conclusions/Significance: Taken together, performance of a single DEX/CRH test does not predict the therapeutic
response. The best predictor for response seems to be an early attenuation of HPA axis activity within 1 or 2 weeks.
However, early improvement of HPA system dysfunction is not a sufficient condition for a favourable response. Since a
substantial part of depressive patients display a persistence of HPA axis hyperactivity at discharge, downregulation of HPA
system function is not a necessary condition for acute clinical improvement either. Our data underline the importance of
HPA axis dysregulation for treatment outcome in major depression, although restoration of HPA system dysfunction seems
to be neither a necessary nor a sufficient determinant for acute treatment response.
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Introduction
According to the corticosteroid-receptor hypothesis of depres-
sion hypothalamic-pituitary-adrenocortical (HPA) system dysreg-
ulation plays an important role in the pathophysiology of
depression [1,2]. In depressed patients, elevated cortisol (COR)
and adrenocorticotrophic hormone (ACTH) concentrations in the
plasma [3–6] or in the cerebrospinal fluid (CSF) [7] have been
found. Additionally, HPA axis hyperactivity is obviously reflected
by elevated urinary free cortisol (UFC) levels, which appear to be
approximately twofold higher in depressed patients as compared
to healthy controls [8]. Further investigations using neuroendo-
crine challenge tests confirmed the hypothesis of a profound HPA
axis dysregulation in depression: Several studies using the
corticotropin-releasing hormone (CRH)-stimulation test reported
a blunted ACTH response whereas the COR stimulation was
indistinguishable from normal controls [9,10]. In contrast to a
reduced ACTH response to CRH, depressive patients show both
an enlargement of the adrenal gland [11,12] and elevated COR
stimulation patterns indicating an enhanced adrenal sensitivity
after challenge with ACTH in most [13–15] but not all [16]
studies. Findings in depressed patients of increased CRH levels in
the CSF [17] and elevated numbers of CRH [18] and arginine-
vasopressin (AVP) [19] expressing neurons in the paraventricular
nucleus of the hypothalamus as well as the observation of reduced
CRH binding sites in the frontal cortex of suicide victims [20] gave
reason to the assumption that depression is characterized by a
hypothalamic overdrive of CRH and/or AVP which in conse-
quence leads to receptor down-regulation in the corticotrophs of
the pituitary gland.
Moreover, it has been suggested that an impaired signalling
pathway via corticosteroid-activated mineralocorticoid and gluco-
corticoid receptors, leading to an impaired negative feedback
regulation of the HPA system, causes this hyperactivity [21]. With
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control in depressed patients is reflected by COR escape from
dexamethasone suppression [22,23] as well as an increased ACTH
and COR release in the combined dexamethasone-suppression/
CRH-stimulation test (DEX/CRH test) [24,25]. The DEX/CRH
test at present is considered to be the most sensitive tool to
demonstrate a disturbed regulation of the HPA axis in depressed
patients and has been shown to have a sensitivity of more than 80% if
subjects are clustered into different age ranges [25].
A gradual down-regulation of HPA axis hyperactivity in
depressed patients as measured by serial DEX/CRH tests has
been demonstrated for tricyclic antidepressants such as amitrip-
tyline [26], doxepin [27], trimipramine [28–31], for the selective
serotonin-reuptake inhibitor paroxetine [32], for tianeptine which
enhances the presynaptic reuptake of serotonin [32], and for the
selective norepinephrine reuptake inhibitor reboxetine [33].
Proponents of the corticosteroid receptor hypothesis of depression
emphasize that a gradual normalization of HPA system dysreg-
ulation as measured by the DEX/CRH test precedes or coincides
with the response to antidepressant treatment and is a necessary
prerequisite for clinical remission to become manifest, whereas
persisting COR hypersecretion during the DEX/CRH test at
discharge in spite of clinical improvement may be an indicator for
an enhanced risk for relapse within the following six months
[34,35]. In addition, in outpatients with clinically remitted major
depression, higher cortisol levels in the DEX/CRH test are
apparently associated with relapse of major depression [36,37].
Interestingly, persisting nonsuppression in the single dexametha-
sone suppression test (DST) also indicates a higher risk for relapse
within the following months [38–43]. It has further been
postulated that antidepressants may exert their therapeutic effects
at least partly through their actions on the HPA system and that all
antidepressants developed so far may have a uniform dampening
impact on HPA axis function irrespective of their type of action
within monoaminergic systems [1,2,44–46].
The present study aims to answer the following questions:
– What is the nonsuppression rate in the DEX/CRH test in
acutely depressed inpatients within the first week after
admission to a psychiatric hospital before starting antidepres-
sant therapy?
– Is the normalization of HPA axis hyperactivity during
antidepressant therapy (as measured by serial DEX/CRH
tests) a necessary condition for clinical response? Are there
depressed patients who respond to antidepressant therapy
although their HPA axis hyperactivity is not attenuated or even
further increased?
– Is the normalization of HPA axis hyperactivity during
antidepressant treatment a sufficient condition for clinical
response? Are there depressed patients who do not respond to
subsequent antidepressant therapy in spite of early improve-
ment of HPA axis dysregulation?
– Is the DEX/CRH test at admission or its change during
antidepressant treatment suitable for prediction of acute
therapeutic response?
Materials and Methods
Sample 1
114 depressed inpatients (53 men, 61 women) aged between 18
and 74 years (mean age 46.48613.81 years) entered the study after
the procedures had been fully explained and written informed
consent had been obtained. The patients were diagnosed by
experienced and trained psychiatrists according to DSM-IV
criteria [47] using the Structured Clinical Interview for DSM-
IV, German version [48]. Inclusion criteria for the depressed
patients were a) a major depressive episode with melancholic
features, according to DSM-IV criteria (DSM-IV: 296.2, 296.3) or
bipolar depression (DSM-IV: 296.5) b) a sum score of at least 18
on the 17-item version of the Hamilton Depression Rating Scale
(17-HAMD) [49] c) exclusion of major medical disorders;
availability of normal laboratory parameters; normal blood
pressure; normal electrocardiogram; and normal encephalogram
d) exclusion of addiction or other comorbid psychiatric diagnoses
e) no psychotropic drugs for at least 3 days before the first DEX/
CRH test with the exception of zopiclone (up to 7.5 mg per day) in
case of sleep difficulties and lorazepam (up to 2 mg per day) in case
of inner tension and anxiety f) exclusion of pregnancy or use of
oral contraceptives g) no use of oral steroid hormones or hormonal
replacement therapy which may influence the results of the DEX/
CRH test. Further clinical characteristics are given in Table 1.
With regard to the DEX/CRH test procedure, participants
received an oral dose of 1.5 mg dexamethasone at 11:00 PM the
day before stimulation. On the following day, patients had to rest
supine on a bed at 02:00 PM. An intravenous catheter was
inserted into the antecubital vein before 02:15 PM and kept open
with physiological saline solution. Blood samples were collected at
03:00, 03:15, 03:30, 03:45, 04:00, and 04:15 PM. Each sample
was immediately centrifuged and stored at 280u C for COR
measurements. At 03:02 PM 100 mg hCRH (Clinalfa AG,
La ¨ufelfingen, Switzerland) reconstituted in 1 ml 0.02% HCL in
0.9% saline were injected within 30 sec. For determination of
COR serum concentrations, a commercial radioimmunoassay kit
was employed (Cortisol-RIA, DPC Biermann, Germany) with a
sensitivity of 8.27 nmol/l. Our intra- and interassay coefficients of
variation were below 5%. We abstained from reporting the ACTH
levels, since COR has been demonstrated to be the best parameter
for analyzing DEX/CRH test results and since most established
cut-off criterions are related to COR levels but not ACTH
concentrations. For the DEX/CRH test the total COR AUC
values (total area under the concentration time curve), determined
by the trapezoid rule according to Simpson [50], were used for
determination of the COR response to the hCRH challenge in the
dexamethasone pretreated patients representing the combined
effects of altered glucocorticoid receptor (GR) function and
hyperdrive of endogenous CRH and vasopressin.
The first DEX/CRH test was administered within the first week
after admission to the Department of Psychiatry and Psychother-
apy, Ludwig-Maximilian-University of Munich. A wash-out
period of 3 days before neuroendocrine testing was mandatory.
After the first DEX/CRH test, the patients were treated according
to clinical judgement with pharmacological and non-pharmaco-
logical antidepressant treatment options at the discretion of the
doctor in attendance. Within the following 4 weeks after the first
DEX/CRH test, 6 patients were treated with SSRIs, 22 patients
with reboxetine, 12 with mirtazapine, 3 with venlafaxine, 3 with
tricyclic antidepressants, 6 with antidepressant and lithium
augmentation, 2 with antidepressant and anticonvulsant augmen-
tation (not carbamazepine), 29 with pharmacological combination
therapies, 8 received electroconvulsive therapy (ECT), and 23
were treated with 2-week transcranial magnetic stimulation (TMS)
followed by antidepressant pharmacotherapy. Clinical response
was defined by a reduction of at least 50% in the 17-HAMD sum
score after 4 weeks of antidepressant treatment. Remission after
week 4 was assumed if the 17-HAMD sum score was lower than
9 points. In case of nonresponse, either an augmentation/
combination strategy or use of another antidepressant with a
DEX/CRH Test and Prediction
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discharged after they had recovered from the depressive episode.
Within the last week before discharge, a second DEX/CRH test
was performed.
The dexamethasone suppression status (suppression versus
nonsuppression) within the DEX/CRH test at admission was
defined by a cut-off criterion of 27.5 ng/ml (,75.3 nmol/l)
applied to the baseline COR level (COR concentration at 03:00
PM, i.e. after administration of 1.5 mg dexamethasone, but
immediately before CRH-challenge) which was derived from a
normative database from the Max-Planck-Institute of Psychiatry in
Munich after correction of a linear bias (Heuser criterion) [25,51].
Moreover, a further criterion was employed which has been
proposed by a Japanese research group [52,53] defining subjects as
nonsuppressors (baseline COR$50 ng/ml [,137.95 nmol/l]),
intermediate suppressors (baseline COR,50 ng/ml and peak
COR$50 ng/ml), and suppressors (peak COR,50 ng/ml) (Ku-
nugi criterion). HPA axis activity at the time of the DEX/CRH
test at discharge was categorized in improvers and nonimprovers
according to the change in the peak COR level after CRH
challenge between DEX/CRH test 1 (admission) and test 2
(discharge). A COR peak improver was defined by a lower COR
peak concentration during test 2; otherwise, a COR peak
nonimprover was presumed. The peak COR level was used for
the categorization into HPA system improvers and nonimprovers
instead of the COR AUC value to be in line with previous
definitions of HPA system improvement in remitted depression
[34,35,54].
Sample 2
Data of the second patient sample have been already reported
in a previous publication of our research group [33]. Clinical and
demographic characteristics of sample 2 are provided in Table 2.
This sample was now re-analyzed with respect to the predictive
value of COR peak improvement during serial DEX/CRH tests
for the therapeutic response. 40 drug-free patients suffering from a
major depressive episode (DSM-IV criteria) were treated with
either reboxetine (8 mg/day; n=20) or mirtazapine (45 mg/day;
n=20) monotherapy for 5 weeks. Before, after 1 week and after
5 weeks of therapy, the dexamethasone/CRH-test was performed
as described above and COR concentrations were measured.
COR peak week 1 improvement was defined as lowering of the
COR peak value between DEX/CRH test 1 (week 0 before
treatment) and test 2 (after 1 week of treatment with either
reboxetine or mirtazapine). COR peak week 5 improvement was
established as a reduction of the COR peak level between test 1
(week 0) and test 3 (week 5). Likewise, COR basal week 1 or week
5 improvement was defined as lowering of the basal COR value at
03:00 PM (after administration of 1.5 mg DEX, but immediately
before hCRH injection) between test 1 (week 0) and test 2 (week 1)
or between test 1 (week 0) and test3 (week 5), respectively. In this
sample, response was defined by a reduction of at least 50% in the
21-HAMD sum score after five weeks of treatment with either
reboxetine or mirtazapine.
Statistics
Demographic and clinical parameters were compared between
suppressors and nonsuppressors (Heuser criterion) or between
COR peak improvers and nonimprovers by the Pearson Chi-
Square test for contingency tables or by Fisher’s exact test with
respect to qualitative variables and by one-way ANOVA for
independent samples with regard to quantitative variables.
Correlations between quantitative variables and endocrinological
parameters were calculated using the rank order coefficient
(Spearman’s rho) since hormonal data were not normally
distributed. Moreover, in sample 2 the baseline-corrected decrease
in 21-HAMD sum scores during 5-week treatment was compared
between COR peak week 1 improvers and nonimprovers and
between COR peak week 5 improvers and nonimprovers using
ANOVAs for repeated measurements. Thereby ‘‘time’’ (week 0–5)
and ‘‘group’’ (improvers vs nonimprovers) were considered as
within-subjects and between-subjects factors with six (‘‘time’’) and
two (‘‘group’’) levels, respectively. Post-hoc tests with contrasts
were additionally performed when ‘‘group’’ was among the
significant influential factors. For the ANOVA procedures, a
correction was applied to the F-value by means of adjusting the
Table 2. Demographic and clinical parameters in 40 inpatients suffering from unipolar depression treated with either reboxetine
(n=20; 8 mg/day) or mirtazapine (n=20; 45 mg/day) for 5 weeks (sample 1) [33].
all patients COR peak week 1 Statistics COR peak week 5 Statistics
(n=40) Im (n=30) NIm (n=10) COR peak week 1 Im (n=24) NIm (n=16) COR peak week 5
diagnoses
MD, first episode 10 9 1 x2=1.600; p=0.206 7 8 x2=0.556; p=0.456
MD, recurrent 30 21 9 17 13
gender (M/F) 17/23 14/16 3/7 x2=0.853; p=0.356 9/15 8/8 x2=0.614; p=0.433
age 47.9614.6 49.7614.3 42.5615.1 F=1.876; p=0.179 49.6614.2 45.4615.3 F=0.767; p=0.387
height [cm] 170.169.2 169.668.3 171.8611.9 F=0.432; p=0.515 169.268.7 171.4610.2 F=0.531; p=0.470
BMI 25.064.1 24.964.2 25.364.2 F=0.063; p=0.803 25.164.2 24.864.2 F=0.076; p=0.784
age of onset 40.0615.0 40.5614.9 38.3615.9 F=0.158; p=0.693 39.5614.3 40.7616.4 F=0.063; p=0.803
number of depressive episodes 2.5861.74 2.6361.92 2.4061.08 F=0.132; p=0.718 2.5061.93 2.6961.45 F=0.109; p=0.743
duration of inpatient status 67.5638.7 64.0635.3 78.2648.1 F=1.013; p=0.321 61.8632.1 76.1646.8 F=1.306; p=0.260
21-HAMD sum score at baseline 24.363.9 24.763.9 22.963.8 F=1.594; p=0.214 25.263.1 22.864.7 F=3.818; p=0.058
Mean6standard deviation (SD) is indicated. Patients are subdivided into COR week 1 Im (improvers)/COR peak NIm (nonimprovers) and into COR week 5 Im/NIm. COR
peak week 1/week 5 Im (=COR peak week 1/week 5 improver): patient with reduction of COR peak value in the DEX/CRH test after 1 week/5 weeks of treatment, as
compared to baseline (week 0). MD=Major Depression. M=male, F=female. BMI=body mass index. 21-HAMD=Hamilton Depression Rating Scale, 21-item version.
Statistics: results of x
2-test or oneway ANOVA are provided.
doi:10.1371/journal.pone.0004324.t002
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(Mauchly W test) was significant indicating a heterogeneity of
covariances (Huyn-Feldt correction). In addition, Cramer’s Phi
was calculated in sample 2 for all patients and also separately in
the reboxetine and the mirtazapine group in order to investigate
putative associations between COR week 1 improvement/COR
week 5 improvement and the clinical outcome after 5 weeks of
treatment (response, remission).
As a nominal level of significance, alpha=0.05 was accepted.
The software program SPSS version 15.0 (SPSS Inc., Chicago,
Illinois, USA) was used for data analysis.
The study was carried out according to the Declaration of
Helsinki (http://www.wma.net) and had been approved by a local
ethics committee (intramural review panel of the Ludwig-
Maximilian-University of Munich, Faculty of Medicine).
Results
Using a cut-off criterion of 75.3 nmol/l (COR level at 03:00
PM) for the definition of nonsuppression in the DEX/CRH test 1
at admission (Heuser criterion), in sample 1 only 28 out of 114
(,24.6%) depressed inpatients were nonsuppressors whereas 86
(,75.4%) acutely depressed patients were suppressors already
before the beginning of antidepressant therapy (Figure 1A).
Moreover, when also using the Kunugi criterion the suppressors
(n=74, i.e. 64.9%) were predominant as compared to nonsup-
pressors (n=19 [,16.7%]) or intermediate suppressors (n=21
[,18.4%]) (Figure 1B). With regard to the DEX/CRH test 1
suppressors and nonsuppressors (categorized by the Heuser
criterion) did not differ in qualitative variables such as diagnoses,
gender distribution, response or remission rates (p.0.05 in x
2-
tests, respectively) (Table 1). Suppressors and nonsuppressors
were also comparable in quantitative parameters such as age,
height, BMI, age of onset, number of depressive episodes, and
duration of inpatient status (p.0.05 in one-way ANOVA,
respectively). However, nonsuppressors were prone to have higher
17-HAMD sum scores at baseline which was statistically
significant (p,0.05) (Table 1). In addition, with respect to test 1
at admission severity of depressive symptoms (17-HAMD sum
scores) was positively correlated with COR AUC values (Spear-
man’s Rho=0.238, p=0.011).
The overall group of depressed inpatients (n=114; sample 1)
showed a significant decrease in COR AUC values during the
DEX/CRH tests between admission and discharge (Figure 2).
However, when the sample was subdivided in COR peak
improvers (COR peak value test 1.COR peak value test 2;
n=69) and in COR peak nonimprovers (COR peak value test
1#COR peak value test 2; n=45), COR peak improvers
displayed a marked reduction in COR AUC values during
inpatient treatment whereas COR peak nonimprovers were
characterized by a pronounced increase in COR AUC values in
spite of clinical recovery and discharge (Figure 2). The same
finding was observed if the patients were classified in patients
receiving psychopharmacological drugs (n=83) and patients
treated with non-pharmacological treatment strategies such as
TMS or ECT (n=31). In the psychopharmacotherapy group,
there were 52 COR peak improvers (mean COR AUC at
admission: 9444.2568606.81 nmol/l6min; mean COR AUC at
discharge: 4599.7564734.71 nmol/l6min) and 31 nonimprovers
(mean COR AUC at admission: 4510.4366065.80 nmol/l6min;
mean COR AUC at discharge: 7790.3967825.23 nmol/l6min).
The non-pharmacological treatment group consisted of 17 COR
peak improvers (mean COR AUC at admission:
12,531.01610,626.87 nmol/l6min; mean COR AUC at dis-
charge: 6442.8268027.38 nmol/l6min) and 14 nonimprovers
(mean COR AUC at admission: 6286.0967256.49 nmol/l6min;
mean COR AUC at discharge: 10,669.75610,608.55 nmol/
l6min). Considering the total sample (n=114), COR peak
improvers and nonimprovers were comparable with respect to
diagnoses, gender distribution, response and remission rates (x2-
tests: p.0.05, respectively) (Table 1). Moreover, there were no
significant differences between COR peak improvers and nonim-
provers regarding age, height, BMI, number of depressive episodes
or 17-HAMD sum score at baseline (oneway ANOVA: p.0.05,
respectively). However, in COR peak nonimprovers a significantly
earlier age of onset of the depressive illness and a significantly
longer duration of time between admission and discharge
(inpatient status) were found (p,0.05, respectively) (Table 1).
Demographic and clinical characteristics of sample 2 (40
depressed inpatients, treated with either reboxetine or mirtazapine
Figure 1. DEX/CRH test at admission in 114 depressed
inpatients. (A) Subdivision into suppressors (n=86) and nonsup-
pressors (n=28) according to the Heuser criterion (nonsuppression:
baseline COR$75.3 nmol/l) as indicated by the cross bar. (B)
Subdivision into nonsuppressors (NS;b a s e l i n eC O R $50 ng/ml
[,137.95 nmol/l]; n=19), intermediate suppressors (IS; baseline
COR,50 ng/ml and peak COR$50 ng/ml; n=21), and suppressors (S;
peak COR,50 ng/ml; n=74) according to the Kunugi criterion.
Baseline COR=COR at 03:00 PM. Mean+/2standard error of mean (SEM)
is given.
doi:10.1371/journal.pone.0004324.g001
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differences between COR week 1/week 5 improvers and
nonimmprovers with regard to diagnoses, gender distribution,
age, height, body mass index, age of onset, number of episodes,
duration of total inpatient status, or severity of depression at
baseline. COR peak week 1 improvement (reduction of the COR
peak value in the DEX/CRH test after 1 week of treatment) was
associated with alleviation of depressive symptoms. Regarding
COR peak week 1 improvement in all patients (n=40), repeated-
measures ANOVA revealed a highly significant ‘‘time’’ effect, i.e.
decrease in 21-HAMD sum scores (F=50.173; d.f.=2.642,
100.401; p,0.001). Moreover, a significant ‘‘group’’ effect was
observed (F=4.638; d.f.=1, 38; p=0.038) indicating a more
pronounced amelioration of depressive symptoms in COR peak
week 1 improvers than in nonimprovers (Figure 3). Post-hoc tests
demonstrated significant differences between COR peak week 1
improvers and nonimprovers at week 1 and week 3 (p,0.05,
respectively). No associations were found between COR peak
week 1 improvement and response or remission rates when
regarding all patients (Cramer’s Phi: p.0.05, respectively;
Table 3). It is also worth to be mentioned that 8 COR peak
week 1 improvers were nonresponders at week 5, i.e. improvement
of COR peak values after 1 week was not a guarantee (sufficient
condition) for clinical response after 5 weeks. When analyzing
separately depressed patients treated with reboxetine (n=20) or
mirtazapine (n=20), significant ‘‘group’’ effects in the repeated-
measures ANOVAs were obtained in the mirtazapine group
(F=5.738; d.f.=1, 18; p=0.028), but not in the reboxetine group
(F=1.410; d.f.=1,18; p=0.250) indicating better alleviation of
depressive symptomatology in COR peak week 1 improvers
treated with mirtazapine than in nonimprovers receiving this
antidepressant. Moreover, in the mirtazapine group (Phi=0.572;
p=0.010), but not in the reboxetine group (Phi=0.121; p=0.589)
a significant association between COR peak week 1 improvement
and response rate after 5 weeks of treatment was demonstrated
(Table 3). Similar results were obtained if COR basal
improvement after 1 week of treatment was used instead.
Figure 3. Analysis of COR week 1 improvers and nonimprovers.
Mean value graphs of the decrease in 21-HAMD sum scores in 40
depressed patients treated with either reboxetine (n=20) or mirtaza-
pine (n=20) for 5 weeks, subdivided into COR week 1 improvers and
nonimprovers. COR week 1 improver=patient with reduction of COR
peak value in the DEX/CRH test after 1 week of treatment, as compared
to baseline (week 0). Mean+/2standard error of mean (SEM) is given.
Significant group effects in the ANOVA for repeated measurements
indicated. *=significant group differences in post-hoc test (p,0.05).
**=highly significant group differences in post-hoc test (p,0.01).
doi:10.1371/journal.pone.0004324.g003
Figure 2. COR AUC values of DEX/CRH tests in 114 depressed
inpatients at admission and at discharge. All patients (n=114),
and subgroups of COR improvers (n=69) and of nonimprovers (n=45)
are shown. Mean+standard error of mean (SEM) is given. COR improver:
reduction of COR peak value in the DEX/CRH test between admission
and discharge. **=highly significant differences in COR AUC values
between admission and discharge (p,0.01).
doi:10.1371/journal.pone.0004324.g002
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significantly associated with better clinical response when
regarding all patients, but also in separate analyses of the
reboxetine and the mirtazapine groups (Table 4).
Analyzing putative associations between the attenuation of
COR peak values at week 5 and antidepressant efficacy in the
whole sample (n=40), there was no significant ‘‘group’’ effect in
the repeated-measures ANOVA between COR peak week 5
improvers and nonimprovers (F=0.358; d.f.=1, 38; p=0.553)
(Figure 4). In addition, when analyzing separately for reboxetine
and mirtazapine, no significant group effects were seen in the
repeated-measures ANOVA between COR peak week 5 improv-
ers and nonimprovers either (reboxetine: F=2.314; d.f.=1, 18;
p=0.146; mirtazapine: F=0.692; d.f.=1, 18; p=0.416). How-
ever, when using Cramer’s Phi as effect size parameter, relevant
associations between COR week 5 improvement and clinical
outcome (response rate, remission rate) could be shown for the
reboxetine group which were nearly significant (response rate:
Phi=0.435; p=0.052; remission rate: Phi=0.546; p=0.051),
whereas no such association were seen in the mirtazapine group
(Table 3).
Using COR basal improvement after 5 weeks of treatment as
parameter for changes in HPA axis activity, the analysis revealed a
significant association between COR basal week 5 improvement
and response/remission in the reboxetine group, but not in the
mirtazapine group (Table 4).
Discussion
One of our main results is the finding that in acutely depressed
inpatients the nonsuppression rate in the DEX/CRH test at
admission was 24.6% (28 out of 114) according to the Heuser
criterion which focuses on the 1.5 mg dexamethasone suppression
status and does not consider the CRH-stimulated COR concen-
trations [25]. When using the Kunugi criterion which also involves
the COR levels after CRH challenge [52,53], the rates of
nonsuppression (16.7%) or intermediate suppression (18.4%) were
somewhat higher if added together (35.1%). However, in any case
the proportion of acutely and severely depressed inpatients who
were identified by nonsuppression in the DEX/CRH test was
much lower in our study than originally expected [25]. In a large
meta-analysis [55] including more than 5,000 depressed patients, a
sensitivity of the single dexamethasone suppression test (DST) of
44% was found using the ‘‘Carroll criterion’’ [56] (nonsuppression
in the DST: COR level .5 mg/dl the day after oral administration
of 1 mg dexamethasone). In the original study of the Max-Planck-
Institute of Psychiatry in Munich, introducing the combined
DEX/CRH test in the literature, it was reported that the
sensitivity of the DEX/CRH test in depression is about 80 to
90% if the control subjects are matched for age and gender and
thus greatly exceeds the sensitivity of the standard DST.
Moreover, a dichotomous cut-off criterion of 40 ng/ml
(110 nmol/l) for the baseline COR concentration in the DEX/
Table 3. COR peak week 1 improvement and COR peak week 5 improvement.
response statistics remission statistics
(NRs/Rs) Cramer’s phi p-value (NRm/Rm) Cramer’s phi p-value
all patients (n=40) 14/26 22/18
COR peak week 1 Im (n=30) 8/22 15/15
Phi=0.303 p=0.056 Phi=0.174 p=0.271
COR peak week 1 NIm (n=10) 6/4 7/3
COR peak week 5 Im (n=24) 7/17 11/13
Phi=0.150 p=0.343 Phi=0.226 p=0.154
COR peak week 5 NIm (n=16) 7/9 11/5
reboxetine group (n=20) 7/13 10/10
COR peak week 1 Im (n=13) 4/9 6/7
Phi=0.121 p=0.589 Phi=0.105 p=0.639
COR peak week 1 NIm (n=7) 3/4 4/3
COR peak week 5 Im (n=14) 3/11 5/9
Phi=0.435 p=0.052 Phi=0.436 p=0.051
COR peak week 5 NIm (n=6) 4/2 5/1
mirtazapine group (n=20) 7/13 12/8
COR peak week 1 Im (n=17) 4/13 9/8
Phi=0.572 p=0.010 Phi=0.343 p=0.125
COR peak week 1 NIm (n=3) 3/0 3/0
COR peak week 5 Im (n=10) 4/6 6/4
Phi=0.105 p=0.639 Phi=0.000 p=1.000
COR peak week 5 NIm (n=10) 3/7 6/4
Response and remission rates after 5 weeks of treatment in 40 depressed patients (sample 2) treated with either reboxetine (n=20) or mirtazapine (n=20) [33]. Patients
are subdivided into COR peak week 1 Im (improvers)/NIm (nonimprovers) and COR peak week 5 Im (improvers)/NIm (nonimprovers). COR peak week 1/week 5 Im
(=COR peak week 1/week 5 improver): patient with reduction of COR peak value in the DEX/CRH test after 1 week/5 weeks of treatment, as compared to baseline
(week 0). NRs=nonresponders; Rs=responders. NRm=nonremitters; Rm=remitters. Statistics: Cramer’s phi as measure of association for the chi-square test is
provided. Significant results (p,0.05) or trends for significance (p,0.10) are given in bold letters.
doi:10.1371/journal.pone.0004324.t003
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proposed to differentiate between suppressors and nonsuppressors
[25,57]. However, in a cross-laboratory validation of the Max-
Planck-Institute it was discovered that the RIA analysis of plasma
COR which had been performed produced concentration values
with a linear bias [35]. Since the biased COR levels were elevated
by a factor of 1.46 in comparison with those at other laboratories,
the cut-off criterion was corrected accordingly and was now
proposed as 27.5 ng/ml (75.3 nmol/l) [32,51].
Even if the corrected cut-off criterion (75.3 nmol/l) is used, in
more recent studies the sensitivity (nonsuppression rate) in acutely
depressed inpatients using the DEX/CRH test is surprisingly low,
possibly lower than the sensitivity of the standard DST (44%), and
amounts to 31.6% (12 out of 38 [32]), 16.6% (35 out of 211 [51]),
or 24.6% (28 out of 114; present study). Moreover, when using the
Kunugi criterion (a) nonsuppression: baseline COR$50 ng/ml
[,137.95 nmol/l]) b) intermediate suppression: baseline
COR,50 ng/ml and peak COR$50 ng/ml c) suppression: peak
COR,50 ng/ml) which considers also the CRH effects within the
combined DEX/CRH test, the rates of nonsuppression or
intermediate suppression in this test (35.1% in our sample) is
lower than expected. In the original investigation of Heuser and
coworkers [25] a sensitivity of 80 to 90% in the DEX/CRH test
was only reached if depressed patients and control subjects were
clustered into different age ranges and highly sophisticated
statistical methods such as multivariate analysis of variance or
discriminant analysis were used. However, these analyses are not
practicable in the clinical situation which requires clear dichoto-
mous variables to differentiate between suppression and non-
suppression. No study has been performed so far confirming the
originally reported high sensitivity of the DEX/CRH test of more
than 80% by using a criterion which is applicable under clinical
conditions. Apparently an ideal cut-off criterion has not been
established yet for the DEX/CRH test.
Nevertheless, a considerable part of acutely depressed patients
shows normally regulated HPA axis activity in the DEX/CRH test
already before antidepressant treatment and may though benefit
from this therapy. In fact the severity of depression was
significantly higher in baseline nonsuppressors than in suppressors
in our study and a significant positive correlation between baseline
21-HAMD sum score and COR AUC values (test 1) could be
demonstrated in our investigation as it has been reported in
previous studies [35,53,58,59]. However, the response and
remission rates in nonsuppressors and suppressors on test 1 were
comparable. Therefore, a single DEX/CRH test performed
within the first week after admission is obviously not suitable for
prediction of the acute treatment response.
The best predictor for acute antidepressant efficacy seems to be
the responsiveness of the HPA system and the change of DEX/
CRH test results within the first one or two weeks of
antidepressant treatment. In our investigation, attenuation of
HPA axis activity (reduction of COR basal value, reduction of
COR peak value) in the whole patient sample after one week of
pharmacotherapy was significantly associated with the subsequent
Table 4. COR basal week 1 improvement and COR basal week 5 improvement.
response statistics remission statistics
(NRs/Rs) Cramer’s phi p-value (NRm/Rm) Cramer’s phi p-value
all patients (n=40) 14/26 22/18
COR basal week 1 Im (n=28) 5/23 12/16
Phi=0.549 p=0.001 Phi=0.373 p=0.018
COR basal week 1 NIm (n=12) 9/3 10/2
COR basal week 5 Im (n=24) 6/18 11/13
Phi=0.257 p=0.104 Phi=0.226 p=0.154
COR basal week 5 NIm (n=16) 8/8 11/5
reboxetine group (n=20) 7/13 10/10
COR basal week 1 Im (n=13) 2/11 5/8
Phi=0.560 p=0.012 Phi=0.314 p=0.160
COR basal week 1 NIm (n=7) 5/2 5/2
COR basal week 5 Im (n=14) 2/12 5/9
Phi=0.663 p=0.003 Phi=0.436 p=0.051
COR basal week 5 NIm (n=6) 5/1 5/1
mirtazapine group (n=20) 7/13 12/8
COR basal week 1 Im (n=15) 3/12 7/8
Phi=0.545 p=0.015 Phi=0.471 p=0.035
COR basal week 1 NIm (n=5) 4/1 5/0
COR basal week 5 Im (n=10) 4/6 6/4
Phi=0.105 p=0.639 Phi=0.000 p=1.000
COR basal week 5 NIm (n=10) 3/7 6/4
Response and remission rates after 5 weeks of treatment in 40 depressed patients (sample 2) treated with either reboxetine (n=20) or mirtazapine (n=20) [33]. Patients
are subdivided into COR basal week 1 Im (improvers)/NIm (nonimprovers) and COR basal week 5 Im (improvers)/NIm (nonimprovers). COR basal week 1/week 5I m
(=COR basal week 1/week 5 improver): patient with reduction of COR basal value in the DEX/CRH test after 1 week/5 weeks of treatment, as compared to baseline
(week 0). NRs=nonresponders; Rs=responders. NRm=nonremitters; Rm=remitters. Statistics: Cramer’s phi as measure of association for the chi-square test is
provided. Significant results (p,0.05) or trends for significance (p,0.10) are given in bold letters.
doi:10.1371/journal.pone.0004324.t004
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reported by Ising and colleagues who found improved HPA system
regulation in a second DEX/CRH test (performed 2 or 3 weeks
after the first test at the beginning of the study) to be associated
with beneficial treatment response after 5 weeks [51,54]. Thus,
performance of two DEX/CRH tests in acutely depressed patients
with an interval of 1 up to 3 weeks seems to be a potential
biomarker with certain significance for the subsequent therapeutic
response.
Since improvement of basal COR, representing a single
dexamethasone suppression test (DST), was at least as powerful
in prediction of therapeutic response as improvement of the COR
peak value (as part of the combined DEX suppression/CRH
stimulation test), one may assume that performance of 2
subsequent dexamethasone suppression tests (DST) may be a
feasible and appropriate predictor of clinical outcome. One single
DST prior to treatment does not reliably predict response to
antidepressant therapy [60]. However, reduction of COR in 2
subsequent DST is of predictive value (our data). As it has been
shown by Carroll and colleagues 4 PM and 11 PM samples are
much better to detect COR nonsuppression (as defined by the
5 mg/dl-criterion in the standard DST) than 8 AM samples [61].
Furthermore, the same research group could demonstrate that
with the 1-mg DEX dose the sensitivity of the DST greatly exceeds
that of the 2-mg DST [61]. Thus, performance of 2 subsequent 1-
mg DST using 4 PM or 11 PM samples [61] or two subsequent
1.5 mg DST using 3 PM samples (our study) may be an easy and
appropriate way to predict therapeutic response. Our results are
confirmed by former studies performing serial DST and suggesting
that downregulation of the HPA system activity as measured by
the DST precedes or coincides with the amelioration of depressive
symptoms [42,62–65].
However, there seem to be differences between antidepressant
drugs which are related to their distinct biochemical properties.
Reboxetine is a norepinephrine reuptake inhibitor which acutely
stimulates COR secretion [66] whereas mirtazapine does not
cause reuptake inhibition but is an antagonist at a2-, 5-HT2-, 5-
HT3-, and histamine H1 receptors and acutely inhibits COR
secretion [67,68]. Apparently, early change of HPA axis activity
(week 1) induced by mirtazapine is related to clinical outcome after
5 weeks whereas 5-week response to reboxetine is associated with
late change in DEX/CRH test results at week 5 (Table 2,
Figure 3, Figure 4). Reuptake inhibiting antidepressants such as
reboxetine, selective serotonin reuptake inhibitors (SSRIs) or
tricyclic antidepressants acutely stimulate cortisol and ACTH
secretion both in healthy subjects [69] and in depressed patients
[70,71] after single administration and may gradually normalize
HPA axis hyperactivity in depressed patients if they are given daily
for several weeks via up-regulation of mineralocorticoid receptor
and glucocorticoid receptor mRNA levels [44,46,72,73], down-
regulation of pro-opiomelanocortin mRNA expression in the
pituitary gland [74], and decrease of CRH gene expression and
CRH mRNA synthesis in the paraventricular nucleus [75,76]
thereby enhancing mineralocorticoid receptor and glucocorticoid
receptor function and restoring the disturbed feedback control. On
the contrary, mirtazapine rapidly reduces HPA axis hyperactivity
in depressed patients within one week which can be explained
most likely by direct pharmacoendocrinological effects of mirta-
zapine such as antagonism at central 5-HT2- and H1-receptors
thereby inhibiting the hypothalamic CRH release. After 5 weeks
of mirtazapine therapy in depressed patients, there is a partial
‘‘rebound’’ phenomenon which can probably be explained by a
compensatory up-regulation of CRH receptors at the pituitary
gland during several weeks of mirtazapine treatment leading to a
Figure 4. Analysis of COR week 5 improvers and nonimprovers.
Mean value graphs of the decrease in 21-HAMD sum scores in 40
depressed patients treated with either reboxetine (n=20) or mirtaza-
pine (n=20) for 5 weeks, subdivided into COR week 5 improvers and
nonimprovers. COR week 5 improver=patient with reduction of COR
peak value in the DEX/CRH test after 5 weeks of treatment, as
compared to baseline (week 0). Mean+/2standard error of mean
(SEM) is given.
doi:10.1371/journal.pone.0004324.g004
DEX/CRH Test and Prediction
PLoS ONE | www.plosone.org 9 January 2009 | Volume 4 | Issue 1 | e4324partial re-enhancement of cortisol and ACTH output after
exogenous administration of 100 mg hCRH during the DEX/
CRH test [33]. Obviously, these different effects on the time
course of HPA axis activity in depressed patients during reboxetine
or mirtazapine treatment are also reflected by diverse associations
with clinical outcome (response related to early changes in HPA
axis activity during mirtazapine treatment and to late changes in
HPA system during reboxetine therapy).
However, two limiting issues have to be pointed out in this
context: First, an early improvement of HPA axis hyperactivity
(e.g. within 1 week of treatment) is not necessarily followed by a
favourable response and therefore is not a sufficient condition for a
beneficial treatment outcome. In the present study, 8 out of 40
depressed patients were classified as COR peak week 1 improvers
but were nonresponders after 5-week treatment with either
reboxetine or mirtazapine. Moreover, in a former study of our
research group, mirtazapine effectively reduced the overshoot of
COR during the DEX/CRH test within 1 week of treatment in 40
depressed inpatients, but this attenuation of HPA axis activity
occurred both in 5-week responders and nonresponders and was
not related to clinical improvement [77]. Therefore, the
importance of an early improvement of HPA axis dysregulation
for the prediction of the acute antidepressant response is limited.
Second, the association between clinical response to the norepi-
nephrine reuptake inhibitor reboxetine and late changes in HPA
system activity (week 5) in our investigation is not confirmed by
other clinical trials investigating the impact of reuptake inhibiting
antidepressants on HPA axis function in depression, since the
decrease in COR levels during serial DEX/CRH tests after 4 to
6 weeks of pharmacotherapy has been found to be comparable in
responders and nonresponders in these studies [26–33].
Moreover, it is remarkable in our study that a considerable
proportion of depressed inpatients (39.5%, i.e. 45 out of 114)
showed a pronounced enhancement of HPA axis activity shortly
before discharge in spite of clinical recovery. Our finding is
supported by other researchers who also found an enhanced HPA
system activity at discharge in a notable part of depressed patients
[34,35], e.g. in 21 out of 74 (28.4%) investigated patients [35]. It is
important to note that in our study HPA system nonimprovers at
discharge were prone to have an earlier age of onset of the
depressive illness and a longer duration of the inpatient stay as
compared to improvers. Furthermore it is known that HPA axis
activity at discharge in spite of clinical improvement is associated
with a higher risk for relapse of depression with regard to medium-
term or long-term outcome [34–37], which has not been
investigated in the present study. Nevertheless attenuation of
HPA axis activity during antidepressant therapy is obviously not a
necessary condition for acute clinical recovery.
Taken together, it can be concluded from our data that the
sensitivity (rate of nonsuppression) of the combined DEX/CRH
test in acutely depressed patients is much lower than originally
reported. Moreover, the performance of a single DEX/CRH test
shortly after admission does not predict the therapeutic response.
The best predictor for response seems to be the early
responsiveness and downregulation of HPA axis activity within
the first 1 or 2 weeks of antidepressant treatment as measured by 2
subsequent DEX/CRH tests. Possibly, the performance of 2
subsequent standard DST may be of comparable predictive value
and can be offered to depressed patients more easily in the clinical
situation. However, the significance of these potential biomarkers
is limited since early improvement of HPA axis dysregulation is
not necessarily followed by a favourable therapeutic response and
is therefore not a sufficient condition for a beneficial treatment
outcome. After 4–6 weeks of antidepressant treatment, the
attenuation of HPA axis activity is comparable in responders
and nonresponders in most studies although an association
between COR week 5 improvement and clinical response to
reboxetine could be demonstrated in the present investigation. At
discharge, a substantial part of depressive patients show even an
enhancement of HPA axis activity in spite of clinical recovery.
Thus, downregulation of HPA system function is not a necessary
condition for clinical improvement. However, patients with
persistence of HPA axis hyperactivity at discharge are known to
have a higher risk for relapse during the following 6 months. Our
data underline the importance of HPA axis dysregulation for
treatment outcome in major depression, although restoration of
HPA system dysfunction seems to be neither a necessary nor a
sufficient determinant for acute treatment response.
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